Kynos Therapeutics, a spinout company launched with Edinburgh Innovations' support, has raised £9 million to progress development of therapies at the interface of inflammation, immunity and metabolism.
GHO Capital Partners, a specialist investor in global healthcare, has invested in RoslinCT, a University of Edinburgh spinout company focused on advanced cell therapies.
An Edinburgh researcher working to develop new therapies for difficult-to-treat cancers is among the first recipients of funding from the $20 million beLAB1407, recently launched to advance life sciences innovation.
What’s your next challenge? Spin in, spin out or start up?
